the includes partner, also in received which million BRIUMVI happy million, U.S. share third It was for over fee licensing revenue joining an for as and that TG, call. our and from $XXX quarter another and today's net good includes net $XX for sales Jenna, Thanks, and everyone, our on thanks morning, U.S. good to quarter of ex we million upfront that I'm was the us $XXX
our and launch team's an launch would the be with pleased I'm understatement. strategy our execution say To of
expectations the set I in future I'm year continue internal We and out outperform year the prior and launch. of our a next to or we're to TG. BRIUMVI at all external the great close for position strong, and to revenue for excited our expectations and believe
the Just everybody, to forms dose. anti-CDXX and twice only to remind can multiple BRIUMVI be treat the is following antibody X-hour per administered first the sclerosis with approved in monoclonal that of relapsing year patients fusion starting
all same. they all the with immunofactor differences begin Epitope trials, noting well that created And engage BRIUMVI cells to health of potency different. is a worth efficacy clinical to care consistent class. as expected profile It's we're that as seeing are binding safety In our amongst ability providers. anti-CDXXs while these provided with binding the resonate what target and same the CDXX robust of protein, not are
quarter don't in and Put only best-in-class whole BRIUMVI's gains. differentiated sales. you share we our believe I the market early as our meaningful full remind together, differentiated with anti-CDXX in attributes of has package supported see profile need we're a second that BRIUMVI to and
on believe early to goal us and So the very toward ultimately gains, that prescribed launch, be still for #X days share driving our well BRIUMVI our anti-CDXX future are for market we positioned here based share. we dynamic
] a had ECTRIMS recent [ is Amis ECTRIMS the Conference, spend TG [ and significant I'd presence this there premier minutes global ] in about a like conference the to talking year. few Milan.
doing well the as people anti-CDXXs early that feedback and as ] personally, the of now many health was positive. repleters were tolerability patients real-world care use really stories great hear other to interact BRIUMVI, about on providers experiencing For me to on the gratifying well It BRIUMVI. convenience overwhelmingly [ was was with anecdotes with and it about are and
II addition well interacting evaluating from MS, our the the trials BRIUMVI present to I providers first data anti-CDXX conference, had additional and opportunity at as who the III the trial, Phase to from another BRIUMVI. ULTIMATE ENHANCE of exploratory relapsing IIIb patients switch the analysis as therapy forms health In from to Phase with care we of in IV
BRIUMVI the before is the as safely. the the dose of need from of as may to XXX-milligram well starting at be IV One goals safety of CDXX for to switching the this another speed a XXX-milligram first trial profile understand infusion dose, patient which the given to evaluate without
dose XXX-milligram skip infusion-related presented data dose was safely any go X-hour early In encouraging, that as there the XXX-milligram given straight reactions reported first delays. very introductory and to demonstrated interruptions no or was that a the in infusion, the dose. demonstrating we were nor could The and XX patients cohort,
sharing year. is next the evaluating the look second cohort for enrolling ] now in X-hour and Again, without need XXX-milligram the more The this from XXX-milligram infusion. data to administered [ is trial ordinary introductory dose, we dose forward and the
of study, effect Interestingly, who entered reported refer off on as crop what people experienced the wearing while gap prior have about their a XX% to CDXX. to the the some patients or IV
to that's for. continue going we're look something out So to
in from we're we move the line, colleagues also had While to Neuraxpharm, our opportunity partner. ex-U.S. the our
approved or relapsing by was As have active with clinical you features. in adult of imaging may the recall, who treat forms June, European in patients to MS, defined disease BRIUMVI Union
the has team market their team, the working Europe. in to we to in continue confident closely with been bring to Neuraxpharm Our BRIUMVI and ability be
is we CNS all experience in extensive success to believe for in broad and countries the their With an and their extensive BRIUMVI Europe. BRIUMVI dedicated presence European growing team positioned major space, in the launch,
early BRIUMVI for awaiting believe is track which we We are the XXXX. on still launch, anxiously
U.K. received treatment happy This BRIUMVI we is BRIUMVI also United share exciting the forward for the are in patients for looking Kingdom. a approval for in to for We new just alternative. that another MS step and
autoimmune And are diseases. candidates, suitability we're and forward, subcu MS Also, be could BRIUMVI for update as indications be before, provide As well the we to our of a brought to an opportunities whether forward expect I've potential able evaluating as into we next that product new mentioned subcutaneous as have we look early additional clinic. in as the formulation and year, BRIUMVI as a we evaluating to pipeline we believe injection. suitable
current room a on we Based anti-CDXX is more more subcu the for option. convenient, tolerable there believe landscape, do
We BRIUMVI. continue view potentially the from to a thus, subcu distinct IV market market and for as expansion as opportunity the attractive
Finally, let me discuss some financial matters.
I in position. some Power, to CFO, our to join detailed us a provide discuss bit Our Sean but revenue wanted update, expectations financial cash will and more just a
with the revenue associated changing their with respect expectations, effects analysts witnessed of have you First, for market BRIUMVI. to revenue many forecast
by source changes sales those quarter been have which about of been from data, despite distributors, of volatility. sales, and warnings driven intra-quarter some usefulness confusion by price has but prior the of a driven Some become this reporting have our
to To as on companies. beginning like promised, third-party I'd our for With quarter with some address November the distributors X, will this, data fourth of that, longer guidance distributor-level no sharing provide be XXXX.
around of the a should partial of to us million is current At time million. we of $XX $XX well million our put for above which consensus approximately the target of for launch. our ahead approximately That $XX million are this set first on time, the sales, revenues bit million 'XX of consensus $XX year $XX million targeting of to and $XX
Now turning position. cash to our
the million $XXX of in cash. we of As end approximately the quarter, had third
our our relatively operate position have last we I revenues we in to cash grow, feel As the trending believe our confident our really of quarterly sight All a and in is a with with continue to OpEx, burn reasonable on from our ability all, line profitability as execute and call, on near plan. down. we here, to stable And we mentioned cash term. business our
Adam provide information about that, more the our With let over to Waldman, will who BRIUMVI call launch. detailed turn Chief Commercialization me our Officer, Adam?
